Sage Journals: Discover world-class research

Abstract

Background:

Patients with inborn errors of metabolism related to Methylenetetrahydrofolate reductase (MTHFR) gene variants are at an increased risk for microvascular complications resulting from diabetic retinopathy. Early intervention with targeted nutritional support, particularly folate supplementation, may help stabilize metabolic function and slow the progression of diseases such as diabetes and hypertension, especially before irreversible structural damage occurs.

Objectives:

To assess the effects of the folate supplement Ocufolin^® on serum markers in patients with Type 2 diabetes (T2D) and mild diabetic retinopathy (MDR).

Design:

Prospective Cohort Study.

Methods:

Ten patients with both MDR and MTHFR polymorphisms (C677T or A1298C) were enrolled in the present study and received Ocufolin^® to address errors in folate methylation metabolism. Patients were excluded if they had a history of other ocular or systemic diseases. Serum biomarkers associated with clinical chemistry (homocysteine, high-sensitivity C-reactive protein [hs-CRP], myeloperoxidase [MPO], fasting insulin, triglycerides, total cholesterol, high density lipoprotein [HDL], low density lipoprotein [LDL], Oxidized-LDL [Ox-LDL], vascular endothelial growth factor [VEGF], D-Dimer, hemoglobin A1c [HbA1c] and glutathione) were measured pre-and post-intervention.

Result:

Treatment with Ocufolin^® resulted in a 23% decrease in serum homocysteine (P = .005), an 18% decrease in hsCRP, a 13% decrease in fasting insulin, a 15% increase in D-Dimer (P = .03) and a 47% decrease in VEGF (P = .04). Additionally, there was a 9% increase in glutathione, a 2% increase in MPO, a 6% reduction in triglycerides, a 3% increase in total cholesterol, a 4% increase in HDL, a 4% increase in LDL, an 8% increase in Ox-LDL. HbA1c did not change.

Conclusion:

Normalizing folate metabolism through Ocufolin^® significantly improved key blood-based biomarkers in patients with diabetic retinopathy. These metabolic improvements may underlie enhanced retinal perfusion and reduced oxidative stress, suggesting potential adjunctive therapeutic benefits for managing vascular retinopathies in this population.

Keywords

B12 CRP diabetic retinopathy glutathione homocysteine L-methylfolate MTHFR

Introduction

Cellular metabolism depends on adequate intake and processing of vitamins, minerals and other nutrients. Disruptions to these processes, and to folate metabolism in particular, can lead to conditions characterized by hypertension, inflammation, and impaired neuroplasticity.^1,2 One of the mechanisms driving these pathological changes is an increase in the vasotoxic compound homocysteine.^3,4 Folate is a crucial mediator in the conversion of homocysteine to methionine in the purine synthesis pathway, and without folate in its methylated form L-methylfolate, homocysteine concentrations will rise.⁵ Elevated homocysteine levels are associated with increased inflammation and oxidative stress which contribute significantly to retinal vascular damage.^6,7 Inadequate folate intake often exacerbates these conditions, necessitating supplementation that is often unachievable through diet alone.^8,9 Folate supplementation, typically by L-methylfolate, can restore disrupted vascular endothelial function, especially in the presence of hyper-homocysteinemia.^6,10 Given the retina’s high metabolic demands, nutritional interventions targeting folate metabolism may protect against ischemia and oxidative injury caused by endothelial insult, potentially slowing or reversing early metabolic dysfunction in retinal vascular conditions such as diabetic retinopathy.^10
-13

C-reactive protein (CRP) and vascular endothelial growth factor (VEGF) are additional biomarkers which increase early in vasculopathic conditions associated with impaired folate metabolism, and are thought to represent oxidative stress and inflammation within retinal and cerebral tissues.^14
-16 Targeted restoration of folate metabolism may mitigate retinal vascular disease progression through reduction of the associated inflammatory processes linked to these biomarkers.

The present study investigated the impact of normalizing folate metabolism in patients with retinal vascular disease and an inborn error to folate metabolism caused by polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene. MTHFR gene mutations significantly impact folate metabolism, leading to elevated homocysteine levels, impaired endothelial function, and increased susceptibility to diabetic complications, including diabetic retinopathy.^11,17 Patients with MTHFR polymorphisms often exhibit increased oxidative stress and inflammation, factors that exacerbate diabetes-related vascular damage, and so, represent a population that may benefit the most from supplementation.³ Ocufolin^® has been developed to alleviate ischemia in the visual system for patients with MTHFR polymorphisms by optimizing folate-dependent metabolic pathways with essential vitamins and cofactors which stabilize methylation.^11,13,18,19 Thus, the present study aimed to assess the effects of the folate supplement Ocufolin^® on serum inflammatory markers in patients with Type 2 diabetes (T2D), (MTHFR) gene variants, and diabetic retinopathy.

Methods

The study was approved by the Institutional Review Board (IRB) of the University of Miami and adhered to all ethical standards set forth in the Declaration of Helsinki. The present study conforms to the “Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement.”²⁰ All participants provided written informed consent after being made aware of the potential risks, uncertainties, and anticipated benefits of participation. Patient recruitment took place at the Bascom Palmer Eye Institute at the University of Miami. Inclusion to the present study required the presence of at least one MTHFR polymorphism (C677C, C677T; A1298A, A1298C) and mild diabetic retinopathy (MDR). The presence of the MTHFR polymorphism was determined through serum genetic screening performed by MyGenetx Laboratory (Franklin, Tennessee, USA). The diagnosis of MDR was confirmed by clinical retinal specialists (JT and ZY) using the criteria established by the American Academy of Ophthalmology and the American Diabetes Association (ADA).²¹ Following confirmation of both MTHFR polymorphisms and MDR, participants underwent a comprehensive review of their medical history, including a structured interview and medication reconciliation, to assess for exclusion criteria. Exclusion criteria included: cloudy corneas, glaucoma, severe cataracts, other retinal vascular diseases, or systemic diseases such as systemic sclerosis or lupus erythematosus. A total of ten patients were enrolled. Demographic information for this cohort is available in Table 1.

Table 1.

Demographic Information of the Study Cohort.

Attribute	Value
Age (years), mean ± SD (range)	59.2 (4.1), 55-66
Gender, male, n (%)	8 (80%)
Race (White), n (%)	6 (60%)
Ethnicity (Hispanic), n (%)	5 (50%)
Smoking (former), n (%)	10 (100%)
Smoking (current), n (%)	0 (0%)
Duration of diabetes (years), mean ± SD (range)	20.0 ± 13.4 (5-44)
Hypertension, n (%)	10 (100%)
Diabetes, n (%)	10 (100%)
HbA1C (%), mean ± SD (range)	7.9 ± 1.2 (5.9-9.9)
Hcy (μmol/L), mean ± SD (range)	11.7 ± 3.5 (5.6-18.4)

Abbreviations: HbA1c, hemoglobin A1c; HCY, homocysteine; MTHFR, methylenetetrahydrofolate reductase.

Patients received Ocufolin^® in a regimen of 3 capsules taken orally once daily for a duration of 6 months and took the regimen at home. Adherence to the intervention was monitored by interview at scheduled follow-up visits to ensure consistent supplement intake. The ingredients are listed in Table 2.¹⁸ Baseline fasting samples were collected initially and after 6 months of Ocufolin^® use, measuring the markers: serum homocysteine (HCY), high-sensitivity hs-CRP, myeloperoxidase (MPO), fasting insulin, triglycerides, total cholesterol, High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), Oxidized Low-Density Lipoprotein (OX-LDL); plasma D-Dimer and VEGF; whole blood hemoglobin A1c (HbA1c), and glutathione. Quest Diagnostics performed all clinical laboratory assessments. Descriptions of each test may be found in the Appendix Table A1.

Table 2.

Ingredients of the Medical Food Ocufolin^®.

Ingredient	Amount
Copper (cupric oxide)	.667 µg
L-methylfolate	900 µg
Lutein	3.35 mg
N-acetyl cystine	180 mg
Pathothenic acid (as calcium-D-pantothenate)	5 mg
Selenium (as L-selenomethionine)	20 µg
Vitamin B1 (thiamine hydrochloride)	1.5 mg
Vitamin B2 (riboflavin)	10 mg
Vitamin B6 (pyridoxal 5’-phosphate)	3 mg
Vitamin B12 (methylcobalamin)	500 µg
Vitamin C (ascorbic acid)	33.3 mg
Vitamin D (cholecalciferol)	1500 IU
Vitamin E (alpha, beta, gamma, and delta tocopherols)	7.5 IU
Zeaxanthin	700 µg
Zinc (zinc oxide)	26.6 mg

Statistical analyses were conducted using Excel (version 2020; Microsoft, Redmond, WA, USA) and SPSS Statistics software (version 27; IBM Corp., Armonk, NY, USA). The Wilcoxon signed-rank test was used to compare the measurements before and after the intake of medical food from the same participants. The Wilcoxon signed-rank test does not assume normality in the data. A P-value of <.05 was considered statistically significant.

Results

Effects on Folate Metabolism

It has been previously shown that increased serum homocysteine (HCY) is the best marker of impaired folate metabolism.²² To determine the effects of Ocufolin^® on folate metabolism, baseline and 6-month follow-up serum levels HCY were measured in patients taking Ocufolin^® for 6 months. The current study found that supplementation yielded a significant 23% decrease (P = .005, Wilcoxon signed-rank test) in serum HCY levels in patients with mild diabetic retinopathy and MTHFR polymorphisms (Figures 1 and 2).

Figure 1.

Change in biomarkers after 6 months of Ocufolin use in patients with early diabetic retinopathy carrying MTHFR polymorphism. HCY, VEGF, and D-Dimer were significantly decreased after 6 months of intake of Ocufolin (P < .05), while other biomarkers showed positive trends.

Figure 2.

Change in biomarkers after 6 months of Ocufolin^® use in patients with early diabetic retinopathy carrying MTHFR polymorphism. HCY, VEGF, and D-Dimer were significantly decreased after 6 months of intake of Ocufolin (P < .05), while other biomarkers showed positive trends.

Effects on Systemic Inflammation

hs-CRP is a general marker of inflammation associated with a variety of diseases.²³ To determine the effects of Ocufolin^® on systemic inflammation, of serum hsCRP in this population of diabetic patients was measured at baseline and 6-month follow-up. We found an 18% reduction in hsCRP (Figures 1 and 2, P = .11). D-Dimer is another inflammatory marker used to assess acute inflammation via the coagulation cascade.²⁴ D-Dimer levels were significantly increased by 15% (P = .03) after 6 months relative to baseline measurement (Table 3; Figures 1 and 2).

Table 3.

All Biomarker Results.

Biomarker	Units	Baseline	6 months	Percent change (%)	P-value
Homocysteine	µmol/L	11.8 ± 3.5	9.1 ± 3.2	23	.01
D-Dimer	mcg/mL	0.4 ± 0.2	0.5 ± 0.2	15	.03
VEGF	pg/mL	87.4 ± 103.2	46.7 ± 41.3	47	.04
hs-CRP	mg/L	1.6 ± 0.9	1.3 ± 0.8	18	.11
HDL	mg/dL	41.0 ± 10.8	42.5 ± 11.6	4	.33
Total cholesterol	mg/dL	125.2 ± 34.1	129.2 ± 32.7	3	.39
Ox-LDL	U/L	35.4 ± 12.5	38.1 ± 14.7	8	.47
Glutathione	µM	670.6 ± 209.3	729.4 ± 289.6	9	.51
MPO	pmol/L	291.9 ± 173.8	297.5 ± 163.0	2	.52
Triglycerides	mg/dL	154.0 ± 74.4	144.0 ± 77.7	7	.58
LDL	mg/dL	60.5 ± 29.0	62.8 ± 30.1	4	.65
Fasting insulin	ulU/mL	64.3 ± 81.9	56.2 ± 56.8	13	.78
HbA1c	%	7.9 ± 1.2	7.9 ± 1.5	0	.96

Abbreviations: Hs-CRP, high sensitivity c-reactive protein; VEGF, vascular endothelial growth factor; MPO, myeloperoxidase antibody; HDL, high density lipoprotein; LDL, low density lipoprotein; Ox-LDL, oxidized LDL; HbA1c, hemoglobin A1c.

Effects on Insulin Metabolism

To determine the effects of 6 months of supplementation on insulin metabolism, we measured the levels of fasting serum insulin in all subjects (Table 3; Figures 1 and 2). Participants experienced a 13% decrease in fasting insulin levels. Hemoglobin A1c (HbA1c) was also measured in all subjects to examine Ocufolin^®’s influence on overall blood sugar levels. HbA1c levels were unchanged after 6 months of supplementation (Table 3).

Effects on Angiogenesis

VEGF is a well-accepted marker of angiogenesis.²⁵ To identify the effects of Ocufolin^® on angiogenesis, we measured plasma levels of VEGF (Table 3; Figures 1 and 2). We found a 47% decrease in plasma VEGF, suggesting decreased angiogenesis and a potential decrease in neovascularization in these subjects. The largest decreases were in patients with the highest baseline plasma VEGF.

Effects on Oxidative Stress

Glutathione is an important antioxidant for protecting cells from oxidative damage to the mitochondria. Mitochondrial neuroprotection is particularly relevant in diabetic retinopathy, where oxidative stress plays a significant role in disease progression.²⁶ Our findings indicated a 9% increase in whole blood glutathione levels, highlighting a systemic improvement of oxidative stress (Table 3). Myeloperoxidase (MPO) activity is an indirect measurement of oxidative stress in the body.²⁷ In the current study, MPO levels increased by 2% (Table 3).

Effects on Lipid Metabolism

Lipid dysregulation is a major indicator of metabolic imbalance, particularly in metabolic syndrome and T2D.²⁸ To determine whether Ocufolin^® is beneficial to lipid metabolism, we measured the levels of triglycerides in this patient cohort after 6 months of therapy. Triglycerides were reduced by 6% (Table 3; Figures 1 and 2). Total cholesterol increased by approximately 3% (Table 3). Low density lipoprotein (LDL) levels were increased by 4% after 6 months. Oxidized LDL (Ox-LDL) levels increased by 8%. High density lipoprotein (HDL) increased by 4%.

Discussion

To the best of our knowledge, this is the first comprehensive biomarker study of a medical food supplement aimed at addressing inborn errors of folate metabolism. The present study found that Ocufolin^®, which contains high doses of vitamins B2, B6, L-methylfolate, B12, vitamin C, zinc, lutein, and n-acetylcysteine, can normalize metabolism and improve serum biomarkers related to inflammation and oxidative stress.

Overall, a 6-month trial of Ocufolin^® in mild diabetic retinopathy patients with MTHFR variants resulted in significant reductions in the inflammatory markers HCY, CRP, VEGF, and glutathione, along with improvements in fasting serum insulin. Reductions in HCY, CRP, and VEGF could potentially lower retinal vasculopathy risk,^14,29
-32 and improved fasting insulin indicates improved insulin resistance and overall metabolic health.³³ These changes likely reflect the impact of increased flow-mediated dilation, improved perfusion, reduced oxidative stress, and reduced ischemia.^6,32,34,35 Further research is necessary to elucidate the optimal impacts of nutrient supplementation on metabolism and physiology in patients at risk for vasculopathy. Moreover, the current study’s sample size was 10 patients, and so future studies will expand upon this limited patient pool.

Homocysteine (HCY) 23% Reduction

HCY is a crucial intermediate in the methylation cycle, affecting the synthesis of cysteine, cystathionine, and methionine.³⁶ Elevated HCY is a biomarker for poor folate metabolism, endothelial dysfunction, systemic vascular health, and small vessel ischemia in the CNS. Elevation of HCY leads to inflammation and brain atrophy.^37,38 High HCY is linked to early hypertension, stroke, and the MTHFR C677T polymorphism.^39,40 In addition, iatrogenic vitamin deficiencies can raise HCY, necessitating supplementation beyond diet.⁴⁰ Meta-analysis shows increased mortality risk above even 1 µmol/L HCY, with significant ischemic stroke risk starting around 50% of the normal upper limit.⁴¹

Folate supplementation improves flow-mediated dilatation in hyper-homocysteinemia.⁶ Systemically, the China Stroke Primary Prevention Trial found that low-dose folate reduced ischemic stroke incidence in hypertensives, particularly with the MTHFR variant.⁴² In the eye, elevated HCY is also a risk factor for retinal microvascular conditions, disrupting the blood-retinal barrier and causing vision loss.¹⁴ B-vitamin supplementation lowers HCY, reducing macular degeneration risk more effectively than AREDS/AREDS2 formulations.⁴³ Vitamins B2, B6, L-methylfolate, and B12 are essential for regulating HCY.⁴⁴ Vitamin D deficiency can also impair folate transport and absorption.⁴⁵ Recent studies suggest optimal serum HCY-targets below 8 µmol/L to mitigate vascular risks.⁴¹

hs-CRP 18% Reduction

Serum CRP is an acute-phase protein biomarker of vascular breakdown, released during tissue injury, and contributes to endothelial dysfunction, vascular stiffness, and hypertension.⁴⁶ Elevated CRP levels damage the blood-brain barrier (BBB) and the blood-retinal barrier.^30,31 CRP is elevated in diabetic retinopathy, particularly in proliferative forms.^47,48 In this study, the average hs-CRP fell 18% after 6 months of Ocufolin^®, likely due to vitamins B1, L-methylfolate, C, D, lutein, and n-acetylcysteine. Supplemental L-methylfolate and thiamin (B1) have shown promise in reducing CRP.^49,50 Antioxidants, including lutein and vitamin C, also lower CRP.^51,52 Moreover, vitamin D deficiency is linked to increased CRP and vitamin D supplementation reduces CRP and other inflammatory markers in Type 2 diabetes.^53,54 Multivitamin formulations may effectively lower CRP,^55,56 potentially restoring normal metabolic states and protecting the visual system.

D-dimer 15% Increase

The D-dimer antigen is the product of cleaved fibrin polymers during terminal fibrinolysis of the coagulation cascade.²⁴ Clinical assays were developed to detect this antigen as an indicator for chronic clot formation such as deep vein thrombosis or pulmonary embolism in emergency departments.^24,57 Elevated D-dimer levels have since been linked to adverse outcomes in aortic dissection patients.⁵⁸ D-dimer has also been linearly correlated to other inflammatory markers such as CRP and immune responses such as elevated neutrophil counts and elevated levels of inflammatory cytokines.^59
-61 This means it might be an effective surrogate for acute inflammation. However, D-dimer elevation has been caveated in many clinical assessment tools. The most widely used assays are considered highly sensitive for the presence of fibrinolysis, but not specific for the presence of any single pathology, including deep vein thrombosis.^57,62 D-dimer levels were elevated in the current study. This may reflect acute inflammation in some patients after 6 months, but could also be the result of unrelated changes in patients’ overall health.

VEGF 47% Reduction

VEGF is a family of vasoactive proteins secreted by the vascular endothelium during anoxia and oxidative stress to promote new vascular growth, enhance perfusion, and reduce ischemia.⁶³ Elevated VEGF increases retinal capillary permeability, exacerbating ischemia.³² While beneficial in most tissues, ocular neovascularization can lead to glaucoma, retinal detachment, retinal edema, and blindness.⁶³ VEGF elevation is linked to the onset and progression of diabetic retinopathy (DR) and neovascular AMD.⁶³ Diabetic patients typically have higher serum VEGF levels, especially those with microvascular complications.⁶⁴ There is ongoing debate regarding the most predictive VEGF test, with some studies showing plasma VEGF correlating well with vitreous levels for predicting proliferative DR progression.⁶⁵ B6 and folate reduce VEGF expression by altering DNA methylation. Additional lowering of retinal VEGF through B6 and folate supplementation may be beneficial.^66,67 B12 supplementation also lowers VEGF and reduces retinal neuron death.⁶⁸ Other nutrients like n-acetylcysteine, vitamin C, and vitamin D also show effectiveness in lowering VEGF.^69,70 Collectively, these may offer important neuroprotective benefits for diabetic retinopathy. In this study, average plasma VEGF may have decreased potentially due to these vitamins. Patients with elevated VEGF showed a more significant reduction, warranting further exploration.

Glutathione 9% Increase

Glutathione is the primary antioxidant that protects cells from oxidative stress caused by reactive oxygen species (ROS). It quenches ROS and is crucial for mitochondrial protection. Most plasma glutathione is synthesized in the liver.⁷¹ Glutathione plays key roles in antioxidant defense, cell cycle regulation, and apoptosis. Severe depletion can lead to oxidative damage and necrotic cell death.^72,73 Impaired synthesis is linked to various conditions, including diabetes.^71,74 Retinal tissues exhibit high metabolic rates, and glutathione depletion can lead to endothelial dysfunction and inflammation.^72,73 Nutrients that effectively increase glutathione levels include L-methylfolate, B2, B6, lutein, n-acetyl cysteine, vitamin C, selenium, zeaxanthin, and zinc,^34,35 and Ocufolin^® contains all of these.

Fasting Serum Insulin, 13% Reduction

Insulin regulates carbohydrate metabolism, and insulin resistance impairs its many functions, affecting all body cells.⁷⁵ Elevated fasting insulin is a key biomarker for insulin resistance and can be more predictive of diabetes than elevated glucose.^76,77 High fasting insulin is associated with increased blood viscosity and reduced perfusion.⁷⁸ Errors in folate metabolism affect glucose metabolism and inflammation. Furthermore, MTHFR C677T polymorphisms correlate with elevated fasting insulin and inflammatory markers.^79,80 Fasting insulin levels in metabolic syndrome are strongly linked to CRP.⁸¹ In this study, the fasting serum insulin reduction potentially reflects improved metabolic function through vitamins L-methylfolate, B12, C, N-acetylcysteine, and zinc.

Triglycerides 6% Reduction

Triglycerides are key lipids linked to cardiovascular and neurovascular diseases. Their elevation is associated with obesity, insulin resistance, metabolic syndrome, and type 2 diabetes.⁸² There is a debate over whether triglycerides are causes or biomarkers of disease. High triglyceride levels coupled with low HDL-C increase cardiovascular risk.⁸² Meleth et al⁸³ found higher serum triglycerides in patients with severe non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME), and Chew et al⁸⁴ noted that elevated triglycerides were linked to earlier onset of retinal hard exudates while lowering serum lipids reduced disease risks. There is consensus that dietary changes are initially preferred over medications.⁸² Folate and vitamin D supplementation have been found to reduce serum triglyceride levels.⁸⁵ N-acetylcysteine has been shown to lower serum and liver triglycerides.⁸⁶

Footnotes

Appendix

Table A1.

Biomarker Information.

Test	Test source	Test method	Reference range	Sample type
MTHFR	Lifetime sciences	PCR—single taqman genotype assay	Wild type; C677C, C677T; A1298A, A1298C	Buccal swab
Homocysteine	Quest diagnostics	Electrochemiluminescence	<10.4 umol/L	Serum
Hs-CRP	Quest diagnostics	Immunoturbidimetric	<1.0 mg/L, lower relative CVR	Serum
			1.0-3.0 mg/L, average relative CVR
			3.1-10.0 mg/L, higher relative CVR
			>10.0 mg/L, infection or inflammation
Serum VEGF	Quest diagnostics	Enzyme ImmunoAssay	31-86 pg/mL	Plasma
Total glutathione	Quest diagnostics	Kinetic, BioAgilytix diagnostics	373-838 μM	Whole blood
Myeloperoxidase antibody (cardio IQ)	Quest diagnostics	Turbidimetreic immunoassay	<470 pmol/L	Plasma
D-dimer	Quest diagnostics	Immunoturbidimetric assay	<.50 μg/mL	Plasma
Total cholesterol	Quest diagnostics	Spectrophotometry	<200 mg/dL	Serum
LDL cholesterol	Quest diagnostics	Martin-Hopkins calculation	<100 mg/dL	Serum
Ox-LDL, cardio IQ	Quest diagnostics	Enzyme linked immunosorbent assay	<60 U/L, optimal	Plasma
			60-69 U/L, moderate
			⩾70 U/L, high
HDL cholesterol	Quest diagnostics	Spectrophotometry	⩾50 mg/dL	Serum
Triglycerides	Quest diagnostics	Spectrophotometry	<150 mg/dL	Serum
Fasting insulin (cardio IQ insulin)	Quest diagnostics	Immunoassay	<18.4 uIU/mL	Serum
HbA1c	Quest diagnostics	Turbidimetric inhibition immunoassay	<5.7%	Whole blood

Abbreviations: MTHFR, methylenetetrahydrofolate reductase; PCR, polymerase chain reaction; hs-CRP, high sensitivity C-reactive protein; CVR, cardiovascular risk; VEGF, vascular endothelial growth factor; LDL, low density lipoprotein; Ox-LDL, oxidized LDL; HDL, high density lipoprotein; HbA1c, hemoglobin A1c.

All tests in the present table were taken at a fasting level apart from the MTHFR swab.

Acknowledgements

Special thanks are extended to the patients who participated in this study.

Ethical Considerations

The study protocol was reviewed and approved by the Institutional Review Board (IRB) at the University of Miami (IRB ID 20070492) and conducted in accordance with the tenets of the Declaration of Helsinki.

Consent to Participate

Informed consent was obtained from all participants prior to their inclusion in the study.

Author Contributions

Jianhua Wang: Conceptualization, methodology, supervision, funding acquisition. Andrew Hoover: Statistical analysis, manuscript revision. Justin H. Townsend: Data collection, statistical analysis, manuscript drafting. Zohar Yehoshua: Review and editing of the manuscript. Kirill Stremousov: Technical support, data curation. Juan Pablo de Rivero Vaccari: Scientific advising, interpretation of inflammasome-related data. Hong Jiang: Clinical evaluation, manuscript revision.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by research grants from Global Healthcare Focus LLC (Wang), NIH Center Grant P30 EY014801, NINDS Grant 1R01NS111115-01 (Wang), and the Research to Prevent Blindness (RPB).

Declaration of Conflicting Interests

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Juan Pablo de Rivero Vaccari is a co-founder and managing member of InflamaCORE, LLC, and has licensed patents on inflammasome proteins as biomarkers of injury and disease as well as on targeting inflammasome proteins for therapeutic purposes. Juan Pablo de Rivero Vaccari is a Scientific Advisory Board Member of ZyVersa Therapeutics Inc.

Data Availability Statement

Data supporting the findings of this study are available upon reasonable request from the corresponding author.

References

Lei

Zhang

Folate and retinal vascular diseases. BMC Ophthalmol. 2023;23:413.

Cai

Liu

Zhang

Zhou

MTHFR gene polymorphisms in diabetes mellitus. Clin Chim Acta. 2024;561:119825.

Liu

Jiang

Townsend

Wang

Improved retinal microcirculation in mild diabetic retinopathy patients carrying MTHFR polymorphisms who received the medical food, Ocufolin^®. Clin Ophthalmol. 2022;16:1497-1504.

Majors

Ehrhart

Pezacka

EH.

Homocysteine as a risk factor for vascular disease. Arterioscler Thromb Vasc Biol. 1997;17(10):2074-2081.

Davis

Stacpoole

Williamson

, et al Tracer-derived total and folate-dependent homocysteine remethylation and synthesis rates in humans indicate that serine is the main one-carbon donor. Am J Physiol Endocrinol Metab. 2004;286(2):E272-E279.

Moat

Lang

McDowell

, et al Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem. 2004;15:64-79.

Wan

, et al The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction. Cardiovasc Diabetol. 2023;22:237.

Reilly

McNulty

Pentieva

Strain

Ward

MTHFR 677TT genotype and disease risk: is there a modulating role for B-vitamins?

Proc Nutr Soc 2014;73:47-56.

Kim

Ahn

Fang

Lee

Park

JS.

Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine (Baltimore). 2019;98:e17918.

10.

Smith

Refsum

Homocysteine – from disease biomarker to disease prevention. J Intern Med. 2021;290(4):826-854.

11.

Shi

Wang

Airen

, et al Nutritional and medical food therapies for diabetic retinopathy. Eye Vision. 2020;7:33.

12.

Liu

Jiang

Townsend

Wang

Improved conjunctival microcirculation in diabetic retinopathy patients with MTHFR polymorphisms after Ocufolin™ Administration. Microvasc Res. 2020;132:104066.

13.

Wang

Brown

Shi

, et al Improving diabetic and hypertensive retinopathy with a medical food containing L-methylfolate: a preliminary report. Eye Vision. 2019;6:21.

14.

Markand

Saul

Roon

, et al Retinal ganglion cell loss and mild vasculopathy in methylene tetrahydrofolate reductase (MTHFR)-deficient mice: a model of mild hyperhomocysteinemia. Invest Ophthalmol Vis Sci. 2015;56:2684-2695.

15.

Reagan

Christensen

Graham

, et al The 677C > T variant in methylenetetrahydrofolate reductase causes morphological and functional cerebrovascular deficits in mice. J Cereb Blood Flow Metab. 2022;42:2333-2350.

16.

Gasecka

Siwik

Gajewska

, et al Early biomarkers of neurodegenerative and neurovascular disorders in diabetes. J Clin Med. 2020;9(9):2807.

17.

Jiang

Liu

Townsend

Wang

Effects of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on retinal tissue perfusion in mild diabetic retinopathy patients receiving the medical food, Ocufolin^®. Clin Ophthalmol. 2023;17:1121-1127.

18.

Liu

Jiang

Townsend

Wang

Effects of Ocufolin on retinal microvasculature in patients with mild non-proliferative diabetic retinopathy carrying polymorphisms of the MTHFR gene. BMJ Open Diabetes Res Care. 2021;9(1):e002327.

19.

Liu

Jiang

Townsend

Wang

Improved conjunctival microcirculation in diabetic retinopathy patients with MTHFR polymorphisms after Ocufolin Administration. Microvasc Res. 2020;132:104066.

20.

Des Jarlais

Lyles

Crepaz

; TREND Group.Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 2004;94(3):361-366.

21.

Chamberlain

Rhinehart

Shaefer

Jr Neuman

Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of medical care in diabetes. Ann Intern Med. 2016;164:542-552.

22.

Lioudyno

Tsymbalova

Chernyavskaya

, et al Association of Increased homocysteine levels with impaired folate metabolism and vitamin B deficiency in early-onset multiple sclerosis. Biochemistry (Mosc). 2024;89:562-573.

23.

Gao

Wang

, et al The predictive value of the hs-CRP/HDL-C ratio, an inflammation-lipid composite marker, for cardiovascular disease in middle-aged and elderly people: evidence from a large national cohort study. Lipids Health Dis. 2024;23:66.

24.

Adam

Key

Greenberg

CS.

D-dimer antigen: current concepts and future prospects. Blood. 2009;113(13):2878-2887.

25.

Shaw

Dwivedi

SKD

Bhattacharya

Mukherjee

Rao

VEGF signaling: Role in angiogenesis and beyond. Biochim Biophys Acta Rev Cancer. 2024;1879:189079.

26.

Kundu

Mandal

Nandi

Osta

Bandyopadhyay

Ray

Oxidative stress in diabetic patients with retinopathy. Ann Afr Med. 2014;13:41-46.

27.

Sugiyama

Okada

Sukhova

Virmani

Heinecke

Libby

Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158(3):879-891.

28.

Zhao

JR.

Cholesterol imbalance in adipocytes: a possible mechanism of adipocytes dysfunction in obesity. Obes Rev. 2010;11:560-567.

29.

Samra

Zaidi

Rajpurohit

, et al Warburg effect as a novel mechanism for homocysteine-induced features of age-related macular degeneration. Int J Mol Sci. 2023;24(2):1071.

30.

Hsuchou

Kastin

Mishra

Pan

C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Cell Physiol Biochem. 2012;30:1109-1119.

31.

Molins

Pascual

Méndez , et al C-reactive protein isoforms differentially affect outer blood-retinal barrier integrity and function. Am J Physiol Cell Physiol. 2017;312:C244-C253.

32.

Miyamoto

Khosrof

Bursell

, et al Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000;156:1733-1739.

33.

Al-Rawaf

Gabr

Iqbal

Alghadir

AH.

High-intensity interval training improves glycemic control, cellular apoptosis, and oxidative stress of type 2 diabetic patients. Medicina (Kaunas). 2023;59(7):1320.

34.

Vezzoli

Dellanoce

Caimi

, et al Influence of dietary supplementation for hyperhomocysteinemia treatments. Nutrients. 2020;12(7):1957.

35.

Tosi

Giustarini

Franci

, et al Superior properties of N-acetylcysteine ethyl ester over N-acetyl cysteine to prevent retinal pigment epithelial cells oxidative damage. Int J Mol Sci. 2021;22(2):600.

36.

Green

Miller

JW.

Folate deficiency beyond megaloblastic anemia: hyperhomocysteinemia and other manifestations of dysfunctional folate status. Semin Hematol. 1999;36:47-64.

37.

Nieraad

Pannwitz

Bruin

Geisslinger

Till

Hyperhomocysteinemia: metabolic role and animal studies with a focus on cognitive performance and decline-a review. Biomolecules. 2021;11(10):1546.

38.

McCaddon

Miller

JW.

Homocysteine-a retrospective and prospective appraisal. Front Nutr. 2023;10:1179807.

39.

Al Hageh

Alefishat

Ghassibe-Sabbagh

, et al Homocysteine levels, H-Hypertension, and the MTHFR C677T genotypes: a complex interaction. Heliyon. 2023;9:e16444.

40.

Yuan

Mason

Carter

Burgess

Larsson

SC.

Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study. BMC Med. 2021;19:97.

41.

Fan

Zhang

Zhong

Association between homocysteine levels and all-cause mortality: a dose-response meta-analysis of prospective studies. Sci Rep. 2017;7:4769.

42.

Huo

Qin

, et al Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313:1325-1335.

43.

Christen

Glynn

Chew

Albert

Manson

JE.

Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women’s Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med. 2009;169:335-341.

44.

George

Majumder

Ice

, et al Genes and genetics in hyperhomocysteinemia and the “1-carbon metabolism”: implications for retinal structure and eye functions. Can J Physiol Pharmacol. 2020;98:51-60.

45.

Eloranta

Zair

Hiller

Hausler

Stieger

Kullak-Ublick

GA.

Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter. Mol Pharmacol. 2009;76:1062-1071.

46.

Hage

Hsuchou

Kastin

Mishra

Pan

C-reactive protein and hypertension C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. J Hum Hypertens. 2014;28:410-415.

47.

King

Mainous

3rd Buchanan

Pearson

WS.

C-reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003;26:1535-1539.

48.

Song

Chen

Liu

Duan

Kong

Relationship between C-reactive protein level and diabetic retinopathy: a systematic review and meta-analysis. PLoS One. 2015;10:e0144406.

49.

Lee

Jung

SM.

Serum folate related to five measurements of obesity and high-sensitivity C-reactive protein in Korean adults. Nutrients. 2022;14(17):3461.

50.

Amirani

Aghadavod

Shafabakhsh

, et al Anti-inflammatory and antioxidative effects of thiamin supplements in patients with gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2022;35:2085-2090.

51.

Block

Jensen

Dalvi

, et al Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med. 2009;46:70-77.

52.

Askari

Faryabi

Mozaffari

, et al The effects of N-acetylcysteine on serum level of inflammatory biomarkers in adults. Findings from a systematic review and meta-analysis of randomized clinical trials. Cytokine. 2020;135:155239.

53.

Jiang

Prabahar

Saleh

SAK

, et al The effects of vitamin D supplementation on C-reactive protein and systolic and diastolic blood pressure in postmenopausal women: a meta-analysis and systematic review of randomized controlled trials. J Acad Nutr Diet. 2024;124:387-396.e5.

54.

Fenercioglu

Gonen

Uzun

, et al The association between serum 25-hydroxyvitamin D3 levels and pro-inflammatory markers in new-onset type 2 diabetes mellitus and prediabetes. Biomolecules. 2023;13(12):1778.

55.

Church

Earnest

Wood

, et al Reduction of C-reactive protein levels through use of a multivitamin. Am J Med. 2003;115:702-707.

56.

Wang

Zhu

Dong

Sun

CH.

Effects of supplementation with multivitamin and mineral on blood pressure and C-reactive protein in obese Chinese women with increased cardiovascular disease risk. Asia Pac J Clin Nutr. 2009;18:121-130.

57.

Imberti

D-dimer testing: advantages and limitations in emergency medicine for managing acute venous thromboembolism. Intern Emerg Med. 2007;2(1):70-71.

58.

Tang

Liu

Shao

Tang

Liu

Shao

Efficacy of CRP in combination with D-dimer in predicting adverse postoperative outcomes of patients with acute Stanford type A aortic dissection. J Cardiothorac Surg. 2022;17(1):71.

59.

Hao

Wei

, et al Inflammation-associated D-dimer predicts neurological outcome of recent small subcortical infarct: a prospective clinical and laboratory study. Clin Neurol Neurosurg. 2024;237:108126.

60.

Bao

, et al Correlation of D-dimer level with the inflammatory conditions: a retrospective study. AME Med J. 2017;2:27.

61.

Zhao

Komissarov

, et al Frontiers | Associations of D-dimer on admission and clinical features of COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Front Immunol. 2021;12:691249.

62.

Brown

Rowe

Reeves

Bermingham

Goldhaber

SZ.

The accuracy of the enzyme-linked immunosorbent assay D-dimer test in the diagnosis of pulmonary embolism: a meta-analysis. Ann Emerg Med. 2002;40(2):133-144.

63.

Witmer

Vrensen

Van Noorden

Schlingemann

RO.

Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1-29.

64.

Mahdy

Nada

Hadhoud

El-Tarhony

SA.

The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye (Lond). 2010;24:1576-1584.

65.

Wang

Chen

Jiang

, et al Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. PLoS One. 2014;9:e110531.

66.

Cui

Wang

Gao

Huang

Folic acid supplementation delays atherosclerotic lesion development by modulating MCP1 and VEGF DNA methylation levels in vivo and in vitro. Int J Mol Sci. 2017;18(5):990.

67.

Ibuki

Lee

Shinojima

Miwa

Tsubota

Kurihara

Rice bran and vitamin B6 suppress pathological neovascularization in a murine model of age-related macular degeneration as novel HIF inhibitors. Int J Mol Sci. 2020;21(23):8940.

68.

Reddy

Prabhakar

Kumar

Reddy

GB.

Effect of vitamin B(12) supplementation on retinal lesions in diabetic rats. Mol Vis. 2020;26:311-325.

69.

Zhu

Zhang

Zhu

Ding

YN.

Effect of antioxidant N-acetylcysteine on diabetic retinopathy and expression of VEGF and ICAM-1 from retinal blood vessels of diabetic rats. Mol Biol Rep. 2012;39:3727-3735.

70.

Irani

Seifer

Grazi

Irani

Rosenwaks

Tal

Vitamin D decreases serum VEGF correlating with clinical improvement in vitamin D-deficient women with PCOS: a randomized placebo-controlled trial. Nutrients. 2017;9(4):334.

71.

SC.

Glutathione synthesis. Biochim Biophys Acta. 2013;1830:3143-3153.

72.

Böhm

Buonfiglio

Voigt

, et al Oxidative stress in the eye and its role in the pathophysiology of ocular diseases. Redox Biol. 2023;68:102967.

73.

Sreekumar

Ferrington

Kannan

Glutathione metabolism and the novel role of mitochondrial GSH in retinal degeneration. Antioxidants (Basel). 2021;10(5):661.

74.

Johnson

Wilson-Delfosse

Mieyal

JJ.

Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients. 2012;4:1399-1440.

75.

Tokarz

MacDonald

Klip

The cell biology of systemic insulin function. J Cell Biol. 2018;217:2273-2289.

76.

Hammel

Stein

Kratzsch

, et al Fasting indices of glucose-insulin-metabolism across life span and prediction of glycemic deterioration in children with obesity from new diagnostic cut-offs. Lancet Reg Health Eur. 2023;30:100652.

77.

Johnson

Duick

Chui

Aldasouqi

SA.

Identifying prediabetes using fasting insulin levels. Endocr Pract. 2010;16:47-52.

78.

Yoshida

Kimura

Aoki

, et al Fasting serum insulin levels and insulin resistance are associated with blood rheology in Japanese young adults without diabetes. J Int Med Res. 2016;44:496-507.

79.

Chedraui

Pérez-López

Escobar

, et al Polymorphisms of the FTO and MTHFR genes and vascular, inflammatory and metabolic marker levels in postmenopausal women. J Endocrinol Invest. 2016;39:885-890.

80.

Chen

Zhang

Wang

, et al C-reactive protein, vitamin B12 and C677T polymorphism of N-5,10-methylenetetrahydrofolate reductase gene are related to insulin resistance and risk factors for metabolic syndrome in Chinese population. Clin Invest Med. 2010;33:E290-E297.

81.

Festa

D’Agostino

Jr Howard

Mykkänen

Tracy

Haffner

SM.

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.

82.

Miller

Stone

Ballantyne

, et al Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292-2333.

83.

Meleth

Agron

Chan

, et al Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46:4295-4301.

84.

Chew

Klein

Ferris

3rd , et al Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996;114:1079-1084.

85.

Asbaghi

Ashtary-Larky

Bagheri

et al. Beneficial effects of folic acid supplementation on lipid markers in adults: A GRADE-assessed systematic review and dose-response meta-analysis of data from 21,787 participants in 34 randomized controlled trials. Crit Rev Food Sci Nutr. 2022;62:8435-8453.

86.

Hang

Shu

Wen

, et al N-acetyl cysteine ameliorates high-fat diet-induced nonalcoholic fatty liver disease and intracellular triglyceride accumulation by preserving mitochondrial function. Front Pharmacol. 2021;12:636204.

Blood Based Vascular Marker Responses to Ocufolin ® in Diabetic Retinopathy Patients Carrying MTHFR Polymorphisms

Abstract

Background:

Objectives:

Design:

Methods:

Result:

Conclusion:

Keywords

Introduction

Methods

Results

Effects on Folate Metabolism

Effects on Systemic Inflammation

Effects on Insulin Metabolism

Effects on Angiogenesis

Effects on Oxidative Stress

Effects on Lipid Metabolism

Discussion

Homocysteine (HCY) 23% Reduction

hs-CRP 18% Reduction

D-dimer 15% Increase

VEGF 47% Reduction

Glutathione 9% Increase

Fasting Serum Insulin, 13% Reduction

Triglycerides 6% Reduction

Footnotes

Appendix

Acknowledgements

Ethical Considerations

Consent to Participate

Author Contributions

Funding

Declaration of Conflicting Interests

Data Availability Statement

References